ADAMTS13: Definition and Role in TTP Diagnosis and Management
ADAMTS13 is a metalloproteinase enzyme that cleaves von Willebrand factor (VWF) multimers, and severe deficiency (<10% activity) is the defining diagnostic criterion for thrombotic thrombocytopenic purpura (TTP), making urgent measurement of ADAMTS13 activity essential for distinguishing TTP from other thrombotic microangiopathies and guiding plasma exchange therapy. 1, 2
What is ADAMTS13?
ADAMTS13 (A Disintegrin and Metalloproteinase with Thrombospondin motifs) is a VWF-cleaving protease that processes ultra-large VWF multimers to prevent excessive platelet activation and microvascular thrombosis. 3 When ADAMTS13 is absent or severely deficient, VWF accumulates in plasma as ultra-large multimers, creating a prothrombotic state that leads to widespread microvascular thrombosis characteristic of TTP. 3, 4
Diagnostic Threshold and Testing Requirements
The critical diagnostic threshold is ADAMTS13 activity <10%, which is indicative of TTP and distinguishes it from other thrombotic microangiopathies. 1, 5
When to Test ADAMTS13
Urgent testing is compulsory when the classic TMA triad is present: non-immune hemolytic anemia (negative Coombs test, elevated LDH, reduced haptoglobin), thrombocytopenia (<150,000/mm³ or 25% reduction), and renal involvement (hematuria, proteinuria, elevated creatinine). 1
Testing should be conducted before initiating plasma exchange whenever possible, as treatment can alter results, though empiric therapy should not be delayed if testing is unavailable. 2, 6
Rapid vs. Reference Standard Assays
Recent advances have introduced rapid ADAMTS13 assays with turnaround times under one hour, which can prevent unnecessary empiric treatment:
HemosIL AcuStar CLIA demonstrates the highest performance with sensitivity 0.98, specificity 0.99, and only 4% discrepant results compared to reference standards. 7
This rapid testing capability allows clinicians to reliably avoid empiric plasma exchange, corticosteroids, and caplacizumab in patients without TTP. 7
Management Guidance Based on ADAMTS13 Activity
Initial Diagnosis and Treatment Decisions
Patients with ADAMTS13 activity <10% require immediate plasma exchange, while those with activity >11% can be safely managed without plasma exchange. 6
A single-center study demonstrated that patients without severe ADAMTS13 deficiency (>11% activity) were safely managed without increased mortality despite receiving no plasma exchange or discontinuing it after short courses. 6
Patients with severe ADAMTS13 deficiency present with distinct features: lower platelet counts, less renal dysfunction, higher neurological abnormalities, and greater hemolysis markers compared to other TMAs. 6
Serial Monitoring During Treatment
Serial ADAMTS13 measurements during plasma exchange provide critical guidance for treatment intensification and diagnosis of complications: 8
If platelet count decreases after initial response despite ongoing plasma exchange, normalized ADAMTS13 activity suggests an alternative diagnosis (e.g., heparin-induced thrombocytopenia from catheter locks). 8
Persistently undetectable ADAMTS13 activity (Day 5-7) in clinically deteriorating patients supports intensification to twice-daily plasma exchange and addition of rituximab. 8
ADAMTS13 antigen levels restore faster than activity levels during recovery; higher antigen levels at initial clinical recovery predict sustained remission versus early exacerbation. 9
Predicting Outcomes and Relapse
Severe depletion of ADAMTS13 antigen (not just activity) during acute episodes is statistically associated with mortality (P=0.0322). 9
Testing for anti-ADAMTS13 autoantibodies helps predict relapse risk, as most acquired TTP cases result from these inhibitory antibodies. 2, 4
Critical Pitfalls to Avoid
Do not exclude TTP based on absence of schistocytes alone - while >1% schistocytes favor TMA diagnosis, their absence has low sensitivity and should not exclude early TMA diagnosis. 1
Do not delay empiric plasma exchange while awaiting ADAMTS13 results in critically ill patients - TTP is life-threatening and requires prompt treatment; however, rapid assays now make same-day results feasible in many centers. 7, 3
Do not assume all patients with thrombocytopenia and hemolysis have TTP - ADAMTS13 testing is essential to distinguish TTP from atypical HUS, STEC-HUS, and secondary TMAs, which have different treatments and prognoses. 1, 6
Special Populations
Pediatric Patients
In children presenting with TMA in the first year of life, consider complement-unrelated genetic causes (DGKE, WT1 mutations) and metabolic disorders (MMACHC) even if ADAMTS13 is normal. 1
Pregnancy-Associated TTP
Congenital TTP patients with pregnancy-onset disease benefit from tailored mid-term prophylaxis during pregnancy, with no relapses observed outside pregnancy. 10
Congenital TTP
Intensive prophylaxis with recombinant human ADAMTS13 (rhADAMTS13) significantly improves relapse-free survival and represents a safe first-line option that reduces long-term organ damage compared to plasma-derived products. 10